Skip Navigation

Center for Immunization Research

Left Background

Dengue Virus Selected Publications

Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD.In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis. 2017 May 8;11(5):e0005584. doi: 10.1371/journal.pntd.0005584

Grifoni A, Angelo M, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Botten J, Boyson J, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf DPatterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. J Virol 2017 Mar 29;91(8). pii: e02133-16. doi: 10.1128/JVI.02133-16

Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.J Virol. 2017 Feb 14, 91(5). pii: e02041-16. doi: 10.1128/JVI.02041-16. PMID: 28031369

Angelo MA, Grifoni A, O'Rourke pH, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D. Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. J Virol 2017 Feb 14, 91(5). pii: e02147-16. doi: 10.1128/JVI.02147-16PMID: 27974563

Durbin AP. A gengue vaccine. Cell 2016 Jun 30 PMID: 2768091

Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, and Durbin AP. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Science Translational Medicine 16 Mar 2016: Vol. 8, Issue 330, pp. 330ra36 DOI: 10.1126/scitranslmed.aaf1517

Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institutes of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. J Infect Dis. 2016 Feb 16.pii:jiw067. (Epub ahead of print) PMID: 26908742

Larsen CP, Whitehead SS, Durbin AP.  Dengue Human Infection Models to Advance Dengue Vaccine Development.Vaccine 2015 Dec 10;;333(50):7075-82. doi: 10.1016/j.vaccine.2015.09.052. Epub 2015 Sep 28.

Schwartz LM, Halloran ME, Durbin AP, Longini IM Jr. The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine, 2015 Jun 26;33(29);3293-3298 doi: 10.1016/j.Vacccine.2015.05.010 PMID: 25989449 PMID: 26424605

Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovechik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. J Infec Dis. 2015 Mar 11;pii:jv082 PMID: 25801652

Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC. Mechanism and Significance of Cell Type-Dependent Neutralization of Flaviviruses. J Virol. 2014 Jul 1;88(13):7210-7220.

Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis. Virology. 2014 Mar;452-453:237-46.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog. 2013 Dec;9(12):e1003761.

Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, Wanionek K, Speicher J, Whitehead SS, Pletnev AG. The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine. 2013 Nov 19;31(48):5772-7.

Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. .Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.Vaccine. 2013 Jul 18;31(33):33

Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE Jr..Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.J Infect Dis. 2013 Jun 15;207(12):1898-908

Adwoa D Bentsi-Enchill; Anna P Durbin; Robert Edelman; Joachim Hombach; John T Roehrig; Julia Schmitz; Peter G Smith; Jeremy Farrar. Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. Vaccine 2013 May 28;31(23):2603-9.

Durbin AP, Mayer SV, Rossi SL, Amaya-Larios IY, Ramos-Castaneda J, Eong Ooi E, Jane Cardosa M, Munoz-Jordan JL, Tesh RB, Messer WB, Weaver SC, Vasilakis N. Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. Virology. 2013 Apr 25;439(1):34-41.

Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.J Infect Dis. 2013 Mar 15;207(6):957-65.

Durbin AP, Whitehead SS. The dengue human challenge model: has the time come to accept this challenge? J Infect Dis. 2013 Mar 1;207(5):697-9

Ellis RD, Wu Y, Martin LB, Shaffer D, Miura K, Aebig J, Orcutt A, Rausch K, Zhu D, Mogensen A, Fay MP, Narum DL, Long C, Miller L, Durbin AP. Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.PLoS One. 2012;7(10):e46094.

Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, et al. Primary Vaccination wtih Low Dose Live Dengue 1 Virus Generates a Proinflammatory, Multifunctional T Cell Response in Humans. PLoS Negl Trop Dis 2012July17; 6(7): e174.Durbin AP, Whitehead SS.Next-generation dengue vaccines: novel strategies currently under development.Viruses.2011 Oct; 3; 10:1800-14.

Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 2011 Sep 23;29(42):7242-50.

Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wainonek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC. A single dose of the DENV-1 candidate vaccine rDEN1?30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. LoS Negl Trop Dis.2011 Aug; 5;8:e1267

van Panhuis WG, Luxemburger C, Pengsaa K, Limkittkul K, Sabchareon A, Lang J, Durbin AP, Cummings DA. Decay and persistence of maternal dengue antibodies among infants in Bangkok. Am J Trop Med Hyg 2011 Aug 85(2): 355-62.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC.A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 2011 Jun;7(6):e1002111.

Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemicJ Infect Dis. 2011 Feb 1;203(3):327-34.

Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol . 2010; 338:129-43. Review

Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Targeted mutagenesis as a rational approach to dengue virus vaccine development. Curr Top Microbiol Immunol. 2010;338:145-58. Review. PMID: 19802584

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg. 2009 Nov;81(5):834-41

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg2009 Nov;81(5):834-41

Durbin AP, Setse R, Omer SB, Palmer JG, Spaeder JA, Baker J, Lessans F, Halsey NA. Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system. Vaccine. 2009 Oct 19;27(44):6143-7

McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg. 2008 Nov;79(5):678-84.

Vasilakis N, Durbin AP, da Rosa AP, Munoz-Jordan JL, Tesh RB, Weaver SC. Antigenic relationships between sylvatic and endemic dengue viruses. Am J Trop Med Hyg. 2008 Jul;79(1):128-32.

Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, diamond MS, Pierson TC. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 2008 May 9 4(5) e000080

Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, Rocha C, Balmaseda A, Harris E. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology. 2008 Jul 5;376(2):429-35. Epub 2008 May 2.

Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, Murphy BR, Pletnev AG. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers Vaccine 2008 Feb 13; 26(7):882-90

Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5(7):518-28.

Durbin AP, McArthur JH, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS. rDEN2/4Delta30(ME), a live attenuated Chimeric Dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006 Nov-Dec; 2(6):255-60

Durbin AP, McArthur JH, Marron JA, Blaney JE Jr., Thumar B, Wanionek K, Murphy BR, Whitehead SS. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.Hum Vaccin. 2006 Jul-Aug; 2(4):167-73.

Blaney JE, Jr., Durbin AP, Murphy BR, Whitehead SS, Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 2006; 19(1):10-32

Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr., Thumar B, Murphy BR, Karron RA. rDEN4Delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005 Mar 1; 191:710-8.

Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, Murphy BR. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg. 2001 Nov;65(5):414-9.

Durbin AP, Karron RA, Thumar B, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. Attenuation and immunogenicity in humans of a live attenuated dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in the 3 untranslated region is highly attenuated and immunogenic in humans. Am J Trop Med Hyg 2001 November; 65:405-13.